The present invention provides a cell-penetrating-peptide multi-arm-PEG medicine conjugate having a general formula I, II, III, IV or V. As compared with linear-chain-type PEG-cell-penetrating-peptide conjugates, the multi-arm PEG has multiple end groups, and has introduction sites for multiple functional groups, which can connect to multiple different active groups. In addition, the cell-penetrating-peptide multi-arm-PEG medicine conjugate to enable the medicine to enter the pathogenetic cells in a targeting manner, to achieve precise treatment. The present invention further provides use of a cell-penetrating-peptide multi-arm-PEG medicine conjugate having targeting ability in preparation of a targeting medicine, especially use of a cell-penetrating-peptide multi-arm-PEG medicine conjugate having targeting ability in the treatment of eye age-related macular degeneration, asthma and pulmonary fibrosis.

The present invention is related to the field of targeted drug delivery. In particular, the particles and compositions described herein are used to deliver drugs to treat the diseases and conditions of interest. These particles and compositions include, but are not limited to, the lipopeptide complexes that mimic human high-density lipoproteins but contain apolipoprotein fragments or combination thereof.

Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (Hypo-BioNVs) or Hypo-exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region, bifunctional or ByTE antibodies, by a viral epitope recognition receptor (VERR), V.sub.HH nanobody, Variable New Antigen Receptor (V.sub.NAR), engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered. A method of making Hypo-BioNVs. A method of treating an individual with cancer, by administering the Hypo-BioNVs to an individual, targeting cancer cells, and treating the cancer. Hypo-BioNVs including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus. A method of treating an individual with cancer, by administering Hypo-BioNVs including CAR receptors having a VERR, V.sub.HH nanobody, V.sub.NAR, engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered with viral receptors of an oncolytic virus to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the Hypo-BioNVs to an individual, and targeting cells to be destroyed or treated for cancer tumors (both liquid and solid), infectious disease, hereditary conditions, autoimmune disease, or metabolic disorders.

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Disclosed herein are chemotherapeutic methods for the treatment of cancer in humans. In at least one specific embodiment, the method can include administering a therapeutic effective amount of one or more p38 inhibitor compound or salt thereof to a human. The method can also include administering a therapeutic effective of one or more IL-6 inhibitor or one or more IL-6 receptor inhibitor or salt thereof to the human. The method can also include administering a therapeutic effective amount of one or more cytotoxic compound or salt thereof to the human.

The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.

Uniform, functional polymer patches can be attached to a fraction of the surface area of living individual cells. These surface-modified cells can cross the blood-brain barrier while remaining viable after attachment of the functional patch. Functional payloads carried by the patch can include a drug. The patch can include one or more polyelectrolyte multilayers (PEMs).

The present invention discloses a hypericin albumin nanoparticle-Escherichia coli serum antibody complex, which is obtained through adding mixed hypericin albumin nanoparticles and rabbit anti-Escherichia colis into ethanediol, irradiating them with carbon ion, setting them at a low temperature for 2 hours after irradiation, centrifuging them at a low temperature, and freezing and drying the precipitates. Its preparation method and application are also provided. The beneficial effects of the present invention are as follows: the present invention provides a hypericin albumin nanoparticle-Escherichia coli serum antibody complex and its preparation method and application, wherein through bacteriostatic test and clinical pharmacodynamic test, it is proved that the effects of target complex is greatly improved compared with that of the prior drug, because the Escherichia coli serum antibodies seek and capture Escherichia coli and the hypericin albumin nanoparticles inhibit and kill Escherichia coli, which precisely attacks Escherichia coli and strengthen the antibacterial effect of hypericin albumin nanoparticle on chicken focus location.